The beneficial effects of glycoprotein IIb/IIIa receptor antagonists in preventing ischemic complications during percutaneous coronary intervention have been established in a series of controlled ...

Outcomes in patients with acute myocardial infarction (AMI) who received adjunctive therapy with glycoprotein (GP) IIb/IIIa-receptor inhibitors during percutaneous coronary intervention (PCI) were ...

Eptifibatide, a platelet glycoprotein IIb/IIIa inhibitor substantially reduces ischemic complications in coronary stent interventions and could become a routine pre-treatment in stent coronary ...

Reductions in ischemia complications achieved with cangrelor in patients undergoing PCI are maintained regardless of whether glycoprotein IIb/IIIa inhibitors were administered, according to recent ...

A small study testing the pharmacodynamic effects of several antiplatelet agents suggests that tirofiban (Aggrastat; Medicure), a glycoprotein IIb/IIIa inhibitor, may provide “more potent and ...

This is a preview. Log in through your library . Abstract On platelets the membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) functions in adhesive interactions with fibrinogen, von Willebrand factor ...

RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, ...

Medicure announced it has received FDA approval for a premixed bolus dose of its glycoprotein IIb/IIIa inhibitor tirofiban HCI for use in patients with non-ST segment elevation ACS. According to a ...

The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial showed that the direct thrombin inhibitor bivalirudin, with provisional glycoprotein (Gp) IIb/IIIa ...

We believe this is the largest naturalistic study of GP IIb/IIIa-receptor inhibitors in AMI patients undergoing PCI to date. The results show that abciximab had a favorable treatment effect on ...